Trials / Recruiting
RecruitingNCT06190275
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors
A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Infusion (GT201) in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Grit Biotechnology · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-arm early exploratory clinical study. designed to evaluate the safety and tolerability of GT201 in combination with a PD-1 inhibitor for the treatment of advanced head and neck tumor subjects with safety and tolerability, as well as pharmacokinetic characterization and efficacy The study consists of two phases. The study consists of two phases, a dose-escalation phase and a dose-expansion phase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GT201 in combination with PD-1 inhibitors | GT201 in combination with a PD-1 inhibitor for advanced head and neck tumors |
Timeline
- Start date
- 2024-05-12
- Primary completion
- 2027-04-30
- Completion
- 2027-04-30
- First posted
- 2024-01-05
- Last updated
- 2026-01-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06190275. Inclusion in this directory is not an endorsement.